Clinical Trial Update: A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects [Phase 2]

View source ↗

Summary

A Phase 2 multiple ascending dose study of BMS-650032 in chronic hepatitis C patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• BMS-650032

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Chronic Hepatitis C | Phase 2 | Status: COMPLETED